Xilio Therapeutics, Inc. (XLO): R&D Expense
$56.04M
Year ended 2025-12-31
$66.83M
Trailing 12 months to 2026-06-30
-1.8%
3-year compound annual growth
+5.0%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $56.04M | +36.0% | 2026-03-23, From 2025-01-01 |
| 2024-12-31 | $41.21M | -21.0% | 2026-03-23, From 2024-01-01 |
| 2023-12-31 | $52.14M | -11.9% | 2025-03-11, From 2023-01-01 |
| 2022-12-31 | $59.20M | +15.7% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $51.19M | +16.6% | 2023-03-02, From 2021-01-01 |
| 2020-12-31 | $43.91M | n/a | 2022-03-01, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $56.04M | +36.0% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $5.57M | +15.6% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $17.19M | -15.2% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $182.78M | +14.5% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $3.72M | +78.0% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $97.58M | +49.4% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $159.29M | +15.3% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $174.09M | +25.7% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $61.12M | -27.7% |
Compare XLO, CPIX, AQST, WVE side by side · Screen every company in Pharmaceutical Preparations ↗